Education
About Us
Working with TipRanks
Follow Us
Inmune Bio (INMB)
:INMB
Earnings Data
Report Date
Feb 26, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.29Last Year’s EPS
-0.4Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive sentiment with significant advancements in CORDStrom and INKmune platforms, as well as promising regulatory pathways for XPro. Financial results showed improved operating efficiency, although challenges with XPro trial results and regulatory delays were noted.Company Guidance
CORDStrom Advances Towards Regulatory Approval
CORDStrom is being prepared for submission for marketing approval in the U.K. and the U.S., showing significant improvements in patients with recessive dystrophic epidermolysis bullosa (RDEB), particularly in reducing itch and improving quality of life.
XPro Potential in Alzheimer's Disease
The XPro platform is making progress with positive results in patients with higher baseline inflammation. The company is pursuing an accelerated regulatory pathway and preparing for an end of Phase II meeting with the FDA.
INKmune Phase II Success in Prostate Cancer
INKmune completed its Phase II trial in prostate cancer ahead of schedule, meeting the primary endpoint and two of the three secondary endpoints.
Financial Position and Reduced Loss
Net loss for the quarter decreased to approximately $6.5 million from $12.1 million in the same period last year. The company has cash reserves of approximately $27.7 million, sufficient to fund operations into Q4 2026.
INMB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
INMB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 30, 2025 | $1.73 | $1.83 | +5.78% |
Aug 07, 2025 | $2.79 | $2.56 | -8.24% |
May 08, 2025 | $7.09 | $6.97 | -1.69% |
Mar 27, 2025 | $7.41 | $7.52 | +1.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Inmune Bio (INMB) report earnings?
Inmune Bio (INMB) is schdueled to report earning on Feb 26, 2026, TBA (Confirmed).
What is Inmune Bio (INMB) earnings time?
Inmune Bio (INMB) earnings time is at Feb 26, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INMB EPS forecast?
INMB EPS forecast for the fiscal quarter 2025 (Q4) is -0.29.